Endocrinology/Hormones

<p>Rentiapril is an orally active inhibitor of angiotensin converting enzyme (ACE), with antihypertensive activity.</p>

<p>Omapatrilat is a metalloprotease ACE and NEP dual inhibitor (Ki: 0.64 and 0.45 nM, respectively).</p>

<p>VPC-14449 is a selective androgen receptor DNA-binding domain (AR-DBD) inhibitor, useful in prostate cancer research.</p>

DS20362725 is a selective estrogen-related receptor alpha (ERRα) agonist, commonly used in the study of metabolic disorders.

<p>Ralaniten (EPI-002), a potent AR-NTD antagonist, inhibits AR with IC50 of 7.4 μM, for CRPC study.</p>

<p>ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal</p>

<p>TC-MCH 7c is an oral, selectable and blood-brain barrier penetrating MCH1R antagonist with IC50 performance of 5.6 nM against hMCH1R, and TC-MCH 7c is a</p>

<p>AZD9567: potent, selective SGRM, oral, IC50=3.8nM, effective in SCW joint inflammation.</p>

<p>Moveltipril (Moveltipril calcium) is a potent angiotensin-converting enzyme (ACE) inhibitor.Moveltipril is converted to captopril in the body for action.</p>

<p>ZD-6888 Hydrochloride, an angiotensin type 1 receptor antagonist, is used potentially for the treatment of hypertension.</p>

<p>Posatirelin, a synthetic peptide, modulates and nourishes brain systems, aiding in vascular dementia research.</p>

<p>GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM,</p>

<p>P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R (IC50: 3.17 μM) and GPR17 (IC50: 1.67 μM) antagonist.</p>

<p>Buloxibutid: a novel AT2 receptor agonist, Ki=0.4 nM (AT2), 10 μM (AT1).</p>

<p>AT-121 is a dual μ-opioid and neuropeptide receptor partial agonist (Kis 16.49 and 3.67 nM, respectively).</p>

<p>G36 is a cell-permeable non-steroidal antagonist of GPER.</p>

<p>Lorundrostat is an aldosterone synthase inhibitor.</p>

<p>Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.</p>

<p>Terlakiren (CP-80,794) is a renin inhibitor that inhibits the potency of human renin and can be used to study neurological disorders of the hypertensive type.</p>

<p>YL-365 is a highly potent and selective GPR34 antagonist that exhibits excellent activity in neuropathic pain models for the study of neurologic diseases.</p>